Bipolar Disorder (Manic Depression) is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bipolar Disorder (Manic Depression) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bipolar Disorder (Manic Depression) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bipolar Disorder (Manic Depression) overview
Bipolar disorder, previously known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood shifts can significantly impact a person’s ability to function in daily life. The exact cause of bipolar disorder is not fully understood, but it is believed to involve a combination of genetic, biological, and environmental factors. Stressful life events or disruptions in neurotransmitter function in the brain may also contribute to the onset of symptoms.
For a complete picture of PTSR and LoA scores for drugs in Bipolar Disorder (Manic Depression), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
